Elham Askari

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Ajai Chari, Cyrille Touzeau, Carolina Schinke et al. · Blood · 2022 · 42 citations

Medicine, Immunology, Pharmacotherapy +12

Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?

Dolores Subirá, Patricia Font, Lucı́a Villalón et al. · Translational research · 2008 · 31 citations

Medicine, Hematology, Immunology +14

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Paula Rodríguez‐Otero, Bhagirathbhai Dholaria, Elham Askari et al. · Blood · 2021 · 21 citations

Medicine, Oncology, Pharmacotherapy +11

Development and validation of a predictive model of in-hospital mortality in COVID-19 patients

Diego Velasco‐Rodríguez, Juan Manuel Alonso‐Domínguez, Rosa Vidal Laso et al. · PLoS ONE · 2021 · 17 citations · Full text

Medicine, Health Sciences, Internal Medicine +17

Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

Adrían Alegre, Gonzalo Benzo, Rafael Alonso et al. · Oncology and Therapy · 2022 · 16 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13